Morgan Stanley Downgrades ResMed (RMD) to Equalweight
Morgan Stanley downgraded ResMed (RMD) from Overweight to Equalweight and lowered its price target, causing the stock to fall 4.5% in afternoon trading.
Key Numbers
Shares of medical device company ResMed (NYSE:RMD) fell 4.5% in the afternoon session after Morgan Stanley downgraded the stock to Equalweight from Overweight and lowered its price target.
Rating Change
| Item | Before | After |
|---|---|---|
| Rating | Overweight | Equalweight |
| Price Target | Not disclosed | Lowered (amount not disclosed) |
Analyst Rationale
The analyst did not provide a specific reason for the downgrade in the published report. However, the downgrade may reflect concerns about the stock's high valuation or expected slowdown in growth in the respiratory device sector.
Context
ResMed (RMD) had performed strongly in recent months, making it susceptible to profit-taking. The medical device sector is also facing increased competition. Other analysts have not yet commented on the downgrade.
What to Make of It
The downgrade by Morgan Stanley may put additional pressure on the stock in the near term, but it does not necessarily reflect a deterioration in the company's fundamentals. Investors are advised to monitor upcoming reports and assess performance independently.
Frequently Asked Questions
Found this useful? Share it